Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study.

The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases - 1 Jan 2000

Silva Giovanni Faria, Villela-Nogueira Cristiane A, Mello Carlos Eduardo Brandão, Soares Elza Cotrim, Coelho Henrique Sergio M, Ferreira Paulo Roberto Abrão, Ruiz Fernando José Goes

Abstract excerpt

BACKGROUND: Tolerance and response to antiviral HCV treatment is poor in advanced fibrosis. The aim of this study was to assess SVR rate and its predictive factors in HCV advanced fibrosis patients treated in real life with full dose PEG-IFN plus RBV and to evaluate the adverse events related to treatment. METHODS: A multicentric, retrospective study was conducted at six university hospitals. METAVIR F3 and F4...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Therapy, Combination
Share to Hepatitis C, Chronic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon-alpha

Share to Liver Cirrhosis

Share to Polyethylene Glycols

Share to Predictive Value of Tests

Share to Ribavirin

Share to Viral Load

Source

Open in PubMed Open full text

Identifiers

PMID: 24055310
DOI: 10.1016/j.bjid.2013.05.007
PMCID: PMC9425191

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study.PMID 24055310Read ↗

Pegylated interferon-α2a plus ribavirin for chronic hepatitis C in a real-life setting: the Hepatys French cohort (2003-2007).Semantic proximity Read ↗

Hepatitis C: efficacy and safety in real life.Semantic proximity Read ↗

Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?Semantic proximity Read ↗

Antiviral treatment of chronic hepatitis C in clinical routine.Semantic proximity Read ↗

Daclatasvir and asunaprevir treatment in patients with severe liver fibrosis by hepatitis C virus genotype 1b infection: Real-world data.Semantic proximity Read ↗

Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: A real life experience.Semantic proximity Read ↗

Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response.Semantic proximity Read ↗

Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium.Semantic proximity Read ↗

Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety Trial.Semantic proximity Read ↗

Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C.Semantic proximity Read ↗

Chronic hepatitis C treated with peginterferon alfa plus ribavirin in clinical practice.Semantic proximity Read ↗

Hepatitis C Viral Kinetic Changes in a Retrospective Cohort Study of Chronic Hepatitis C Virus Egyptian Patients on Pegylated Interferon and Ribavirin Therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.